Engineered immune cells take on childhood leukemia and lymphoma

NCT ID NCT04787263

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a therapy where a child's own immune cells are modified in a lab to recognize and attack cancer cells. The treatment is for children with B-cell acute lymphoblastic leukemia or certain types of lymphoma that have come back or not responded to standard treatments. The goal is to find a safe dose and see if the therapy can shrink or eliminate the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CAR T-cells (a type of immune cell modified to target cancer cells)
What this could lead to
If successful, this could offer a new treatment option for children with hard-to-treat B-cell cancers, potentially leading to remission.
What could go wrong
This is an early-phase trial with only 32 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • IRCCS Ospedale Pediatrico Bambino Gesù

    Roma, 00165, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.